Meldonium vs Roxadustat
Head-to-head comparison of Meldonium (3-(2,2,2-Trimethylhydrazinium)propionate) and Roxadustat (Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Meldonium | Roxadustat |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | 3-(2,2,2-Trimethylhydrazinium)propionate | Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor |
| Molecular Weight | 146.19 Da | 352.35 Da |
| Half-Life | ~3-6 h | ~12-16 h |
| Amino Acids | N/A | N/A |
| Typical Dose | 500-1000 mg/day in divided oral doses | 70-100 mg orally three times weekly |
| Route | Oral/IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 70 | 180 |
| Research Status | Clinical | Clinical |
Meldonium Benefits
- ✓improves exercise tolerance
- ✓may reduce ischemic fatigue
- ✓supports metabolic efficiency
- ✓may aid recovery
Roxadustat Benefits
- ✓induces endogenous EPO
- ✓improves iron handling
- ✓raises hemoglobin
- ✓may improve exercise tolerance
Meldonium Dosing
500 mg orally daily|500 mg orally twice daily|500-1000 mg/day in divided doses
Roxadustat Dosing
70-100 mg orally 3x weekly|Titrate by hemoglobin response|Monitor iron indices regularly
Meldonium Side Effects
- ⚠GI upset
- ⚠headache
- ⚠palpitations
Roxadustat Side Effects
- ⚠nausea
- ⚠hypertension
- ⚠thrombotic events
Research Overview
Meldonium
Clinical literature focuses on cardiometabolic support and exercise tolerance rather than direct anabolic effects. Any endurance benefit is thought to come from altered substrate handling and improved tolerance to stress.
Roxadustat
Large clinical studies support roxadustat for anemia, especially in chronic kidney disease populations. Direct VO2 max enhancement data in healthy athletes are limited, so its performance effects remain mostly inferential.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.